Use of Oral Antidiabetic Drugs (Metformin and Pioglitazone) in Diabetic Patients with Breast Cancer: How Does It Effect on Serum Hif-1 Alpha and 8Ohdg Levels?

Abstract

<br/><b>Objective</b>: The aim was to investigate indicators related to DNA damage and cancer pathogenesis in Type IIdiabetes cases with breast cancer. It was planned to evaluate the relationship between these markers with oralantidiabetic drugs. Research Design and <br/><b>Methods</b>: Fourty patients and 10 healthy individuals were included inthe study. HIF-1α and 8-OHdG are examined in blood samples taken from these individuals with an ELISA Kit.Statistical analysis of data was performed with 95% confidence using Windows package program SPSS 15.0.<br/><b>Results</b>: HIF-1α parameters were found to be meaningfully higher in the patient group than the controls in bothpretreatment and posttreatment periods (p<0.05). No significant differences in terms of 8-OHdG between patientsand controls. However, posttreatment serum HIF-1α ve 8-OHdG levels was found lower than pretreatmentlevels in patients receiving metformin, but not with pioglitazone. Conversely, serum 8-OHdG levels decreasedsignificantly in these patients. When patients were evaluated according to the treatment groups (pioglitazone vs.metfformin) no significant differences in terms of serum HIF-1α and 8-OHdG levels between treatment groups.<br/><b>Conclusions</b>: HIF-1α levels decreased significantly in the patient group receiving metformin. However, therewas no significant difference in terms of HIF-1α levels in the patients receiving pioglitazone.